Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Mi2000 TICI - Post-market Implantation Study (TUPIS)

11. november 2026 opdateret af: MED-EL Elektromedizinische Geräte GmbH

This Post-Market Clinical Follow-up (PMCF) investigation aims to further collect evidence on safety and performance of the Mi2000 TICI. This PMCF investigation will prospectively collect clinical data from the use of the Mi2000 TICI and related devices.

This PMCF investigation is performed on a cochlear implant system newly introduced to the market, which was previously studied in two pre-market clinical investigations. The purpose of the current clinical investigation is to collect further evidence by collecting additional clinical data on the use of the Mi2000 TICI.

Studieoversigt

Status

Rekruttering

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

22

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

  • Belgien
      • Liège, Belgien, 4000
        • Ikke rekrutterer endnu
        • Centre Hospitalier Universitaire de Liège, Department ORL
        • Kontakt:
          • Philippe Lefebvre, Dr.med.
    • Belgium
      • Antwerp, Belgium, Belgien, 2650
        • Ikke rekrutterer endnu
        • UZA Antwerpen
        • Kontakt:
          • Vincent van Rompaey, Prof. Dr.
  • Polen
    • Poland
      • Nadarzyn, Poland, Polen, 05-830
        • Ikke rekrutterer endnu
        • The Institute of Physiology and Pathology of Hearing
        • Kontakt:
          • Piotr Skarzynski, Prof. Dr.
  • Tyskland
      • Würzburg, Tyskland
        • Ikke rekrutterer endnu
        • Universitätsklinikum Würzburg
        • Kontakt:
          • Kristen Rak, Prof. Dr.
    • Bavaria
      • München, Bavaria, Tyskland, 81377
        • Rekruttering
        • Klinikum der Universität München, Campus Großhadern
        • Kontakt:
          • Joachim Müller, Dr.med.
  • Østrig

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Minimum age of eighteen (18) years at time of enrolment
  • Bilateral sensorineural hearing loss with no or limited benefit from a hearing aid (>70 dB HL PTA4(500, 1000, 2000, 4000Hz))
  • Post-lingual onset of deafness
  • No or limited benefit from hearing aids for less than 10 years and an expected benefit from cochlear implantation
  • A maximum score of 50% on a word test in the language of the test center in the ear to be implanted in the best aided condition
  • Fluency in the test language with excellent proficiency, as appropriate to perform speech testing
  • Functional auditory nerve
  • General health condition, psychological and emotional condition deemed compatible with the treatment and tests performed in this study
  • Pre-operative assessment according to the local professional standards
  • Candidate is highly motivated and has realistic expectations about the expected benefit of the implant and shall understand the importance of returning to the implant center for regular speech processor programming, assessment sessions and training
  • Realistic expectations, as deemed appropriate by the implanting surgeon/implant board
  • Signed and dated informed consent before the start of any study-specific procedure

Exclusion Criteria:

  • Lack of compliance with any inclusion criterion

  • Previously having received an implant on the location chosen for placing the cochlear implant

  • Having received a hearing implant from another manufacturer than MED-EL on the contralateral ear

  • Pre-existing condition known to necessitate MRI scans after implantation of the Mi2000 TICI

  • Women being pregnant or nursing

  • The individual is known to be intolerant of the materials used in the implant or other required accessories

  • Absence of cochlear development

  • The cause of deafness is non-functionality of the auditory nerve and/or the upper auditory pathway

  • Medical contra-indications to middle ear and/or inner ear surgery, and/or anesthesia

  • External or middle ear infections are present

  • The tympanic membrane is perforated in the ear to be implanted

  • Anatomic abnormalities are present that would prevent appropriate placement of the stimulator housing in the bone of the skull, or prevent placement of the chosen electrode array into the cochlea (including ossification of the cochlea)

  • The psychological status of the individual is unstable

  • The individual has unrealistic expectations

  • Acute cholesteatoma

  • History of vestibular schwannoma

  • Unstable Meniere's disease

  • Auditory Neuropathy

  • Epilepsy not responding to treatment

  • Permanent inability and/or unwillingness to participation in post-operative care and rehabilitation

  • Known intellectual disability and/or psychological diseases

  • Participation in other pharmacological clinical trials within four weeks prior to enrolment

  • Anything that, in the opinion of the Investigator, would

    • place the subject at increased risk
    • preclude the subject's full compliance with or completion of the study

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: TICI recipients

Participants in this clinical investigation will be implanted with an Mi2000 TICI totally cochlear implant
Enhed: Cochlear Implantation

Participants in this clinical investigation will receive a totally implantable cochlear implant.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Word Test in Quiet
Tidsramme: Pre-op to 6 months after first fitting

Word recognition in quiet, on a scale from 0 to 100% correct, higher scores indicate better outcomes
Pre-op to 6 months after first fitting
Sentence Test in Noise
Tidsramme: Pre-op to 6 months after first fitting

Oldenburg Matrix Test, results measured in dB signal-to-noise ratio (SNR) with a range of +30 to -10 dB SNR, lower values indicating better outcomes
Pre-op to 6 months after first fitting

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Health Utility Index Mark 3 (HUI3)
Tidsramme: Pre-op to 6 months after first fitting

Health utility scale:

1.00: Perfect health. 0.00: Death. Negative values: States worse than death.
Pre-op to 6 months after first fitting
Nijmegen Cochlear Implant Questionnaire (NCIQ)
Tidsramme: Pre-op to 6 months after first fitting

Disease specific Quality of Life, overall score is on a scale from 0 to 100, higher numbers indicating better outcomes
Pre-op to 6 months after first fitting
Change in body sound perception
Tidsramme: through study completion, an average of 12 months after first fitting

Participant reported scale on body sound perception (0 - no disturbance to 10 - very disturbing)
through study completion, an average of 12 months after first fitting
Change in stigma perception
Tidsramme: through study completion, an average of 12 months after first fitting

Participant reported scale on stigma perception (0 - no stigmatization to 10 - strong stigmatization)
through study completion, an average of 12 months after first fitting
Change in comfort perception
Tidsramme: through study completion, an average of 12 months after first fitting

Participant reported scale on stigma perception (0 - not comfortable to 10 - very comfortable)
through study completion, an average of 12 months after first fitting

Andre resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Word test in quiet
Tidsramme: through study completion, an average of 12 months after first fitting

Word recognition in quiet, on a scale from 0 to 100% correct, higher scores indicate better outcomes
through study completion, an average of 12 months after first fitting
Sentence Test in Noise
Tidsramme: through study completion, an average of 12 months after first fitting

Oldenburg Matrix Test, results measured in dB signal-to-noise ratio (SNR) with a range of +30 to -10 dB SNR, lower values indicating better outcomes
through study completion, an average of 12 months after first fitting
Health Utility Index Mark 3 (HUI3)
Tidsramme: through study completion, an average of 12 months after first fitting

Health utility scale:

1.00: Perfect health. 0.00: Death. Negative values: States worse than death.
through study completion, an average of 12 months after first fitting
Nijmegen Cochlear Implant Questionnaire (NCIQ)
Tidsramme: through study completion, an average of 12 months after first fitting

Disease specific Quality of Life, overall score is on a scale from 0 to 100, higher numbers indicating better outcomes
through study completion, an average of 12 months after first fitting
Speech, Spatial, Quality of Hearing (SSQ12)
Tidsramme: through study completion, an average of 12 months after first fitting

Speech, Spatial and Quality of hearing scale from 0 to 10, higher numbers indicating better outcomes
through study completion, an average of 12 months after first fitting
Hearing Implant Sound Quality Index (HISQUI)
Tidsramme: through study completion, an average of 12 months after first fitting

Sound quality score ranging from 19 (very poor sound quality) to 133 (very good sound quality)
through study completion, an average of 12 months after first fitting
Tinnitus Functional Index (TFI)
Tidsramme: through study completion, an average of 12 months after first fitting

Tinnitus questionnaire measures the severity and negative impact of tinnitus on a 0 (Not a Problem / Slight Tinnitus) to 100 (Very Big Problem / Very Severe Tinnitus) scale
through study completion, an average of 12 months after first fitting
Audiogram
Tidsramme: through study completion, an average of 12 months after first fitting

Pure-tone air-conduction hearing thresholds will be measured in each ear. The threshold is the lowest sound level, in decibels hearing level (dB HL), at which the participant responds. The outcome is the threshold at each frequency. Higher thresholds mean poorer hearing; lower thresholds better hearing.
through study completion, an average of 12 months after first fitting

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

MED-EL Elektromedizinische Geräte GmbH

Efterforskere

  • Studieleder: Florian Schwarze, MED-EL

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

11. november 2026

Primær færdiggørelse (Anslået)

1. januar 2029

Studieafslutning (Anslået)

1. januar 2029

Datoer for studieregistrering

Først indsendt

15. oktober 2026

Først indsendt, der opfyldte QC-kriterier

22. oktober 2026

Først opslået (Faktiske)

27. oktober 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

12. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

11. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Nøgleord

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • MED-EL_CRD_2026_03

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

produkt fremstillet i og eksporteret fra U.S.A.

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner